home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  April 26, 2024
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 467 active entries

Sepragen Corp.

1205 San Luis Obispo Ave
Hayward, CA 94544
United States of America, California

Phone: 510-475-0650
Fax: 510-475-0625

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

Sepragen Signs Supply Agreement with Pall Corporation for Bench-Top Chromatography Systems.

HAYWARD, Calif.”(BUSINESS WIRE)”Feb. 22, 2005 -- Sepragen Corporation (Pink Sheets:SPGNA), a provider of patented technology and equipment for purification needs in the biotech and nutraceutical industries, today announced that it has signed a multi-year agreement with filtration and purification industry leader, Pall Corporation (NYSE:PLL). Under the agreement, Sepragen will develop and manufacture bench top process development chromatography systems for Pall. The products, which augment Pall™s extensive capabilities, will be sold and supported by Pall™s global sales and technical support network.

Ken Frank, President of Pall BioPharmaceuticals said, "We are very pleased with our new alliance with Sepragen, which has a track record of developing innovative products for chromatography. The addition of these small-scale systems to our chromatography line expands our ability to satisfy customers™ increasing needs for purification systems that span the drug development and production process."� Products that scale up easily from the lab to the manufacturing floor are one key to the industry™s ability to bring new drugs to market quickly.

Of this arrangement, Vinit Saxena, CEO of Sepragen, had this to say: "The Pall alliance provides validation of our technology, position and capability. The alliance will help us significantly enhance our revenue and, with the help of Pall™s marketing and distribution channels, will enable us to take a greater share in the sizeable and rapidly growing biotech market."

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductors, water purification, aerospace and broad industrial markets. Total revenues are $1.8 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at www.pall.com.

About Sepragen

Sepragen (Pink Sheets:SPGNA) is a pioneer in bioseparations providing innovative equipment and instruments to biotech companies and processing know-how and technology to nutritional and dairy companies. The Company holds over 14 patents related to its core technology.


Selected Categories:

Product Company   Service Company
Biotech
- General

Last update of this entry: December 01, 2005

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.